hBM-MSCs reduced NEC incidence and severity in a concentration-dependent manner in a neonatal mouse NEC model. (A) NEC incidence in all the experimental groups based on NEC histological grade (Control, n = 16; NEC + PBS, n = 15; NEC + hBM-MSCs (0.5 × 106), n = 23; NEC + hBM-MSCs (1 × 106), n = 15). (Control vs. NEC + PBS; NEC + PBS vs. NEC + hBM-MSCs (1 × 106); NEC + hBM-MSCs (0.5 × 106) vs. NEC + hBM-MSCs (1 × 106)). (B) Representative histological sections from each treatment group (hematoxylin/eosin staining). Image magnification: upper panels, 40×; lower panels, 100×. hBM-MSCs: human bone marrow-derived mesenchymal stromal cells; NEC: necrotizing enterocolitis; PBS: phosphate-buffered saline. *** p < 0.001 (Fisher’s Exact test).